FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	-	,

	OMB APP	ROVAL
	OMB Number:	3235-0287
	Estimated average be	urden
-	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ordentlich Peter						2. Issuer Name and Ticker or Trading Symbol Syndax Pharmaceuticals Inc [SNDX]								(Checl	tionship of Reporting all applicable) Director		Pers	10% Owner	
(Last) (First) (Middle) C/O SYNDAX PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 02/15/2023 X Officer (give title below) below) Chief Scientific Officer								Peony					
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3							4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)										olicable		
(Street) WALTHAM MA 02451												X	Form filed by More than One Reporting						
(City)	(S	tate)	(Zip)												Person	l			
		Tab	ole I - I	Non-Deri	vativ	e Se	curiti	ies A	cquir	ed, D	isposed o	f, or B	enefi	cially	Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		Benefic Owned		es ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code V		Amount	(A) or (D) Price			Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock			02/15/2	2023		02/15/2023		M		7,572	A	\$6	5.38	7,	7,572		D		
Common Stock 02/15/2					2023	02/15/2023		023	S ⁽¹⁾		7,572	D	\$25.8	25.8437(2)		0.00		D	
Common Stock 02/15/2					2023	23 02/15/2023		M		17,428	A	\$	\$7.2		17,428		D		
Common Stock 02/15/202					2023	02/15/2023		023	S ⁽¹⁾		17,428	D	\$25.8	\$25.8437(2)		0.00		D	
		•	Table								sposed of, , convertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code (8)	action	5. Nu of Deriv Secu Acqu (A) or Dispo	5. Number			cisable and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ount 8	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Ame or Nun of Sha						
Stock Options (Right to buy)	\$7.2	02/15/2023			M			17,428	(3)	06/01/2025	Common Stock	17,	428	\$25.8437	0.00		D	
Stock Options (Right to	\$6.38	02/15/2023			M			7,572		(3)	02/06/2029	Common	7,5	572	\$25.8437	0.00		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
- 2. The sale prices ranged from \$25.53 to \$26.10.
- 3. This option is fully vested

Remarks:

/s/ Michael A. Metzger, Attorney-in-Fact

02/17/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).